GS-5245
Hepatitis B
Phase 2Active
Key Facts
About Gilead Sciences
Founded in 1987, Gilead Sciences has established itself as a premier biopharmaceutical company with a strong track record of bringing transformative medicines to market. The company generates substantial revenue from its portfolio of approved drugs, particularly in HIV and hepatitis, while investing heavily in R&D to advance next-generation therapies in oncology, inflammation, and infectious diseases. With a market capitalization of over $170 billion and a diversified pipeline, Gilead continues to be a major player in the global pharmaceutical landscape.
View full company profileOther Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| ABX196 | Abivax | Preclinical |
| ARO-HBV | Arrowhead Pharmaceuticals | Phase 1 |